Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 32, 2023 - Issue 5
Submit an article Journal homepage
1,902
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study

Kyung-Sang Yua Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of KoreaView further author information
,
Byungwook Kima Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of KoreaView further author information
,
Dongseong Shinb Clinical Trial Center, Gachon University Gil Medical Center, Incheon, Republic of KoreaView further author information
,
Min Kyu Parkc Department of Clinical Pharmacology and Therapeutics, Chungbuk National University Hospital, Cheongju, Republic of KoreaView further author information
,
Jun Gi Hwangc Department of Clinical Pharmacology and Therapeutics, Chungbuk National University Hospital, Cheongju, Republic of KoreaView further author information
,
Min-Gul Kimd Center for Clinical Pharmacology, Jeonbuk National University College of Medicine and Hospital, Jeonju, Republic of KoreaView further author information
,
Hyewon Chunge Department of Clinical Pharmacology and Toxicology, Korea University Guro Hospital, Seoul, Republic of KoreaView further author information
,
JongLyul Ghimf Department of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan, Republic of KoreaView further author information
,
Jae-Yong Chungg Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of KoreaView further author information
,
Josef S. Smolenh Department of Medicine, Medical University of Vienna, Vienna, AustriaView further author information
,
Gerd R. Burmesteri Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, GermanyView further author information
,
SungHyun Kimj Medical Science Division, Celltrion, Inc., Incheon, Republic of KoreaView further author information
,
YunJu Baek Clinical Planning Department, Celltrion, Inc., Incheon, Republic of KoreaView further author information
,
DaBee Jeonk Clinical Planning Department, Celltrion, Inc., Incheon, Republic of KoreaView further author information
,
JaeKyoung Yool Pharmacovigilance Department, Celltrion, Inc., Incheon, Republic of KoreaView further author information
,
GoEun Yangk Clinical Planning Department, Celltrion, Inc., Incheon, Republic of KoreaView further author information
,
JiHun Baem Biometrics Center, Celltrion, Inc., Incheon, Republic of KoreaView further author information
&
Edward Keystonen Department of Medicine, University of Toronto, Toronto, Ontario, CanadaCorrespondence[email protected]
View further author information
 show all
Pages 429-439 | Received 17 Jan 2023, Accepted 05 May 2023, Published online: 26 May 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.